{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T21:30:05Z","timestamp":1776288605979,"version":"3.50.1"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objective<\/jats:title>\n<jats:p>The study aimed to compare the characteristics and prognosis between patients with second primary lung cancer following Hodgkin\u2019s lymphoma and those with primary lung cancer.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Materials and methods<\/jats:title>\n<jats:p>Using the SEER 18 database, the characteristics and prognosis were compared between the second primary non-small cell lung cancer following Hodgkin\u2019s lymphoma (HL-NSCLC) (n = 466) and the first primary non-small cell lung cancer (n = 469,851)(NSCLC-1), as well as between the second primary small cell lung cancer following Hodgkin\u2019s lymphoma (n = 93) (HL-SCLC) and the first primary small cell lung cancer (n = 94,168) (SCLC-1). Comparisons of categorical variables were performed using Chi-square or Fisher\u2019s test. Continuous variables were compared using the Mann-Whitney U test. Overall survival (OS) was estimated using the Kaplan-Meier method, and the difference between groups was analyzed by log-rank test.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>HL-NSCLC group had more males than NSCLC-1 group, and the median age of HL-NSCLC group was younger than that of NSCLC-1 group. Patients with HL-NSCLC showed inferior OS than those with NSCLC-1 (median: 10 months vs. 11 months, P = 0.006). Both HL-SCLC and SCLC-1 groups had poor prognosis, with median OS of 7 months (P = 0.4). The 3-year cumulative risks of death from any cause for patients with the latencies from HL to NSCLC of 0 to 5 years, &gt;5 to 10 years, &gt;10 to 15 years, &gt;15 to 20 years, and&gt;20 years were 71.8%, 82.6%, 86.8%, 85.7% and 78.5%, respectively(P = 0.020).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>HL-NSCLC patients had worse prognosis than NSCLC-1 patients, while HL-SCLC patients shared similar characteristics and survival with SCLC-1 patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0285766","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T17:28:52Z","timestamp":1684344532000},"page":"e0285766","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["The characteristics and survival of second primary lung cancer after Hodgkin\u2019s lymphoma: A comparison with first primary lung cancer using the SEER database"],"prefix":"10.1371","volume":"18","author":[{"given":"Ling","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daquan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9810-1050","authenticated-orcid":true,"given":"Haizhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"issue":"5","key":"pone.0285766.ref001","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3322\/caac.21565","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"69","author":"KD Miller","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"pone.0285766.ref002","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1200\/JCO.2013.53.1194","article-title":"Treatment of Hodgkin lymphoma: a 50-year perspective","volume":"32","author":"GP Canellos","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"pone.0285766.ref003","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3322\/caac.21438","article-title":"Hodgkin lymphoma: A review and update on recent progress","volume":"68","author":"S Shanbhag","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"pone.0285766.ref004","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","author":"BM Aleman","year":"2007","journal-title":"Blood"},{"issue":"26","key":"pone.0285766.ref005","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second Cancer Risk Up to 40 Years after Treatment for Hodgkin\u2019s Lymphoma","volume":"373","author":"M Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"issue":"31","key":"pone.0285766.ref006","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1200\/JCO.2011.34.8268","article-title":"Second cancer risk after chemotherapy for Hodgkin\u2019s lymphoma: a collaborative British cohort study","volume":"29","author":"AJ Swerdlow","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"pone.0285766.ref007","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1182\/blood-2010-04-278796","article-title":"Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study","volume":"117","author":"SM Castellino","year":"2011","journal-title":"Blood"},{"issue":"16","key":"pone.0285766.ref008","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1200\/JCO.2002.09.038","article-title":"Second malignant neoplasms among long-term survivors of Hodgkin\u2019s disease: a population-based evaluation over 25 years","volume":"20","author":"GM Dores","year":"2002","journal-title":"J Clin Oncol"},{"issue":"14","key":"pone.0285766.ref009","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.2016.70.9709","article-title":"Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History","volume":"35","author":"A Sud","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"pone.0285766.ref010","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/annonc\/mdh273","article-title":"Solid tumors in patients treated for Hodgkin\u2019s disease: a report from the German Hodgkin Lymphoma Study Group","volume":"15","author":"K Behringer","year":"2004","journal-title":"Ann Oncol"},{"issue":"10","key":"pone.0285766.ref011","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(05)70387-9","article-title":"Lung cancer after treatment for Hodgkin\u2019s lymphoma: a systematic review","volume":"6","author":"P Lorigan","year":"2005","journal-title":"Lancet Oncol"},{"issue":"6","key":"pone.0285766.ref012","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2002-02-0634","article-title":"Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors","volume":"100","author":"AK Ng","year":"2002","journal-title":"Blood"},{"issue":"3","key":"pone.0285766.ref013","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/jnci\/94.3.182","article-title":"Lung cancer following chemotherapy and radiotherapy for Hodgkin\u2019s disease","volume":"94","author":"LB Travis","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"pone.0285766.ref014","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/j.cllc.2022.08.003","article-title":"Predictors of Secondary Lung Cancer Among Hodgkin Lymphoma Survivors: A Nationwide Analysis","volume":"23","author":"Y Alnimer","year":"2022","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"pone.0285766.ref015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s12094-015-1342-7","article-title":"Lung cancer and other second neoplasms after treatment of Hodgkin lymphoma","volume":"18","author":"E Almagro-Casado","year":"2016","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"pone.0285766.ref016","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/annonc\/mdi155","article-title":"Clinical course of thoracic cancers in Hodgkin\u2019s disease survivors","volume":"16","author":"P Das","year":"2005","journal-title":"Ann Oncol"},{"issue":"7","key":"pone.0285766.ref017","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdr551","article-title":"Lung malignancies after Hodgkin lymphoma: disease characteristics, detection methods and clinical outcome","volume":"23","author":"JD Schoenfeld","year":"2012","journal-title":"Ann Oncol"},{"issue":"24","key":"pone.0285766.ref018","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1002\/cncr.26257","article-title":"Survival after second primary lung cancer: a population-based study of 187 Hodgkin lymphoma patients","volume":"117","author":"MT Milano","year":"2011","journal-title":"Cancer"},{"issue":"10","key":"pone.0285766.ref019","first-page":"1027","article-title":"Molecular changes in second primary lung and breast cancers after therapy for Hodgkin\u2019s disease","volume":"9","author":"C Behrens","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"pone.0285766.ref020","unstructured":"Curtis RE. New malignancies among cancer survivors: SEER cancer registries, 1973\u20132000: US Department of Health and Human Services, National Institutes of Health \u2026; 2006."},{"issue":"5","key":"pone.0285766.ref021","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/annonc\/mdl023","article-title":"Computed tomography screening for lung cancer in Hodgkin\u2019s lymphoma survivors: decision analysis and cost-effectiveness analysis","volume":"17","author":"P Das","year":"2006","journal-title":"Ann Oncol"},{"issue":"5","key":"pone.0285766.ref022","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa1102873","article-title":"Reduced lung-cancer mortality with low-dose computed tomographic screening","volume":"365","author":"National Lung Screening Trial Research T","year":"2011","journal-title":"N Engl J Med"},{"issue":"21","key":"pone.0285766.ref023","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1056\/NEJMoa1209120","article-title":"Results of initial low-dose computed tomographic screening for lung cancer","volume":"368","author":"National Lung Screening Trial Research T","year":"2013","journal-title":"N Engl J Med"},{"issue":"36","key":"pone.0285766.ref024","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1200\/JCO.2014.56.7644","article-title":"Identification of independent primary tumors and intrapulmonary metastases using DNA rearrangements in non-small-cell lung cancer","volume":"32","author":"SJ Murphy","year":"2014","journal-title":"J Clin Oncol"},{"key":"pone.0285766.ref025","first-page":"e13235","article-title":"Second cancers in Hodgkin\u2019s lymphoma long-term survivals: A 60-year single institutional experience with real-life cohort of 871 patients","volume":"2018","author":"K Petrakova","journal-title":"Int J Clin Pract"},{"key":"pone.0285766.ref026","article-title":"Lung cancer survival and sex-specific patterns in Portugal: A population-based analysis","author":"T Guerreiro","year":"2021","journal-title":"Pulmonology"},{"issue":"7","key":"pone.0285766.ref027","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/JTO.0b013e3181dc213e","article-title":"Sex, histology, and time of diagnosis are important factors for prognosis: analysis of 1499 never-smokers with advanced non-small cell lung cancer in Japan","volume":"5","author":"T Kawaguchi","year":"2010","journal-title":"J Thorac Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0285766","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T17:29:37Z","timestamp":1684344577000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0285766"}},"subtitle":[],"editor":[{"given":"Wen-Wei","family":"Sung","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,5,17]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0285766","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,17]]}}}